Teva Announces Successful Results of Phase III Study of Its Long-Acting G-CSF Product in Breast Cancer Patients

Teva Pharmaceutical Industries Ltd. TEVA announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim compared to pegfilgrastim. Lipegfilgrastim, a long acting granulocyte colony-stimulating factor, was added to Teva's portfolio through the acquisition of ratiopharm. It is being developed to reduce the duration of severe neutropenia in cancer patients undergoing chemotherapy. Neutropenia is a condition in which the number of white blood cells is decreased, leaving patients more susceptible to potentially life-threatening bacterial infections.